PROBLEMS IN TX CASE STUDY. JB is a 42 yo BM who was admitted to

Similar documents
Diagnosis and Treatment of Tuberculosis, 2011

Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012

Drug Interactions Lisa Armitige, MD, PhD November 17, 2010

Treatment: First Line Drugs TUBERCULOSIS TREATMENT: MEDICATIONS & REGIMENS TREATMENT: GENERAL PRINCIPLES MECHANISM OF ACTION MID 27

Debbie Onofre, RN, BSN March 18, TB Nurse Case Management March 17 19, 2015 San Antonio, Texas

Anti Tuberculosis Medications: Side Effects & adverse Events

Drug Side Effects and Toxicity

Treatment of Tuberculosis

DRUG SIDE EFFECTS AND TOXICITY

5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH

Standard TB Treatment

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

Pre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI:

At the end of this session, participants will be able to:

TB Nurse Case Management San Antonio, TX. TB Medications and Adverse Effects

Pharmacology and Pharmacokinetics of TB Drugs Part I

Managing Complex TB Cases Diana M. Nilsen, MD, RN

TB Grand Rounds. Reynard McDonald, MD & Henry Fraimow, MD January 30, Outline

Treatment of Tuberculosis

Treatment of Active Tuberculosis

Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012

CHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

Treatment of Tuberculosis Disease. Treatment of Tuberculosis. Decision to Treat Initiation of Therapy 1

SA TB Guidelines The interface with Advanced Clinical Care

Pediatric TB Intensive San Antonio, Texas October 14, 2013

6/8/2018 TB TREATMENT. Bijan Ghassemieh, MD Seattle TB Clinical Intensive Disclosures. None

Case presentation. Dr Connie Haley, MD, MPH Dr Gautam Kalyatanda, MD

Supplementary Appendix

Pediatric TB Intensive Houston, Texas

LTBI in Special Populations John Nava, MD October 5, 2010

Official ATS/CDC/IDSA Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (Nahid et al, CID 2016)

LTBI Videos-Treatment

Managing the Patients Response to TB Treatment

Dosage and Administration

Tuberculosis medications: adverse drug reactions

Treatment of Tuberculosis

Tuberculosis: A Provider s Guide to

Case Management of the TB/HIV Infected Patient

TB Nurse Case Management

Analysis. Answers. Action. Saturday Night Fever. Shaka Brown Capital Congress

Treatment of Tuberculosis, 2017

Management of MDR TB in special situations. Dr Sarabjit Chadha The Union

Fundamentals of Tuberculosis (TB)

Shu-Hua Wang, MD, MPH &TM Assistant Professor of Medicine The Ohio State University

Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011

Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014

Treatment and Monitoring

Dana G. Kissner, MD Detroit Department of Health & Wellness Promotion Wayne State University

104 MMWR December 17, 2004

Antimycobacterial drugs. Dr.Naza M.Ali lec Dec 2018

Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015

Patient History 1. Patient History 2. Social History. The Role of Surgery in the Management of TB. Reynard McDonald, MD & Paul Bolanowski, MD

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014

Early Identification and Prevention of Drug-to-Drug Interactions in a tertiary care hospital. RadhikaSoanker*, SubbalaxmiMVS $.

Antituberculous Agents

Tuberculosis Reporting, Waco-McLennan County Public Health District TB Control WMCPHD (254)

Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014

HEALTH SERVICES POLICY & PROCEDURE MANUAL

Dose Counting Exercise Elizabeth Foy, RN, BSN September 8, 2016

Management of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore

Anti Tuberculosis Medications

Pharmacokinetics (PK) and Pharmacodynamics (PD) in the Treatment of Tuberculosis

MANAGEMENT OF DILI in TB/HIV coinfected patients. Chimoio 31 August 2017 by Dr Ndiviwe Mphothulo

Errors in Dx and Rx of TB

TB and Comorbidities Adriana Vasquez, MD April 12, 2018

TB Intensive San Antonio, Texas August 7-10, 2012

Peter Mere Latham English physician & educator

Tuberculosis: update 2013

Concomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications.

Medication Administration and Adverse Reactions Alisha Blair, LVN September 28, 2011

Overcoming the Challenges in Access to TB Drugs for Children

MDR TB/HIV INTEGRATION MDR TB WORKSHOP 18 SEPTEMBER 2015

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition

Outline 8/2/2013. PK/PD PK/PD first-line drug กก PK/PD กก

Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016

What He Said: Rifampin versus Rifapentine

Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015

TB in the Patient with HIV

Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017

Therapeutic Drug Monitoring for Improving TB Treatment Outcomes: A Concept for a Randomized Clinical Trial before Clinical Implementation

Marcos Burgos, MD has the following disclosures to make:

TB Special Situations Case Discussions

Contact Investigation and Prevention in the USA

Treatment of Tuberculosis

Co-morbidities & Special Situations

TB Intensive San Antonio, Texas

Diagnosis and Medical Management of Latent TB Infection

Tuberculosis Tools: A Clinical Update

TB BASICS: PRIORITIES AND CLASSIFICATIONS

Treatment of Tuberculosis

Anri Uys (MSc Pharmacology, BPharm NWU) Medicines Information Centre, Division of Clinical Pharmacology University of Cape Town

Tuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013

Chapter 5 Treatment for Latent Tuberculosis Infection

Tuberculosis Intensive November 17 20, 2015 San Antonio, TX

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2013

TB Nurse Case Management. March 7-9, Diagnosis of TB: Ken Jost Wednesday March 7, 2012

Introduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Pediatric Tuberculosis: The Essentials October 8, 2014

Transcription:

Why TB Drugs Fail Part 2 Why TB Drugs Fail OR How We Fail TB Drugs (and Tb Patients) 1

PROBLEMS IN TX FAILURE TO RESPOND TB MENINGITIS RENAL FAILURE HEPATITIS CAN T SWALLOW PILLS GI INTOLERANCE ADVERSE DRUG REACTIONS ALLERGIES DRUG INTERACTIONS CASE STUDY JB is a 42 yo BM who was admitted to hospital following a new onset seizure. He complains of persistent headaches over the past month and a history of 30 lb weight loss and chronic cough. He is diabetic and has a history of alcoholism. He has a negative PPD but an abnormal chest x-ray and AFB positive sputum smears and culture. 2

CASE STUDY JB is started on 4-drug TB therapy and referred to his CHD. JB does well and is smear and culture negative at 2 months. EMB and PZA are stopped. However, at 3 months he is again loosing weight, his headaches have returned and he is now smear and culture positive. Question 1 The most likely reason for JB s treatment failure is: 1. Non compliance 2. Resistance 3. Low serum drug levels 4. Inadequate tissue penetration 3

Diabetes Reduced immunity Changes in gi emptying/absorption Effects of severe hyperglycemia Altered protein binding TB and TB drugs can make diabetes more difficult to control Some antidiabetic drugs can contribute to hepatitis Alcohol/Drug Abuse Gastritis Effect on metabolism Malnutrition Decreased immunity Increased risk of side effects Hepatitis Peripheral neuropathy Non-compliance 4

THICK WALLED CAVITY QUESTION #2 JB had an MRI and his CNS TB has gotten worse. Which drug would NOT be a good choice to cross the BBB in therapeutic quantities? 1. INH 2. RIFAMPIN 4. ETHAMBUTOL 4. PZA 5. STREPTOMYCIN 5

TB MENINGITIS Tuberculomabiopsy proven-with surrounding edema 6

MIC Versus Concentration DRUG PK [ ] MCG/ML MCG/ML MIC INH 3 5 0.01 0.25 RIF 8 24 0.06 0.25 PZA 20 60 6.2 50 EMB 3 5 0.5 2.0 STM 35 45 0.25 2.5 CAP 35 45 1.25 2.5 OFLOX 8 10 0.25 2.0 CNS PENETRATION INH 90-100 % RIF 10-25% PZA 75-100% EMB 10-50% STM <10% QUINILONES 10-50% CYCLOSERINE 80-90 % 7

Protein Binding Aminoglycoside ~30% Cipro/Floxin i 20-40% EMB 10-15% INH 10-15% PZA 50% PAS 50-60% RIF 84-90% CNS PENETRATION DRUG EXPECTED SERUM [ ] MCG/ML PB EFFECTIVE SERUM [ ] MCG/ML % CSF normal Effective conc norm % CSF inflamed EFFECTIVE CSF [ ] INFLAMED MIC INH 3-5 (4) 10-15% 3.4 100% 4 100% 4 0.2 RIF 8-24 (10) 85% 1.5 10% 1 20% 2 0.5 EMB 2-6 (4) 25% 3 0-10% 0.4 50% 2 5 PZA 20-60 (40) 50% 20 75% 30 100% 40 20 LEVOFLOXACIN 8-12 (10) 30% 7 15-20% 2 45% 4.5 MOXIFLOXACIN 3-5 (4) 40% 1.6 50% 2 CYCLOSERINE 20-35 (25) 0% 25 90% 22.5 100% 25 8

Smiling Face Brain CT LOW SERUM DRUG LEVELS WRONG DOSE REDUCED ABSORPTION DIABETES/HIV GI DISEASE/SURGERY MALNUTRITION LAXATIVE ABUSE DRUG-FOOD INTERACTIONS DRUG-DRUG INTERACTIONS INCREASED METABOLISM / EFLUX VOMITING NON-COMPLIANCE 9

INTESTINAL WALL SMALL INTESTINE PAPILLI P-Glycoproteins 10

CYP 450 System QUESTION #3 WHICH OF THE FOLLOWING CAN BE TAKEN WITHOUT REGARD TO MEALS? 1. INH 2. RIFAMPIN 3. MOXIFLOXACIN 4. ETHAMBUTOL 11

Bioavailability RIF 100%(FASTING) 70% (FED) NFV 20%(FASTING) 80% (FED) Absorption Food/Drug Interactions Most often caused by Iron Calcium Magnesium Aluminum Zinc Fat Low/high ph Protein Most effected INH, EMB, RIF Ofloxacin/ciprofloxacin Indinavir, saquinavir, nelfinavir, lopinavir, ddi, tenofovir 12

BEWARE OF FLUIDS DAIRY PRODUCTS Ca FORMS INSOLUABLE COMPLEXES WITH RX FOOD SUPPLEMENTS Protein, Ca and other minerals ORANGE JUICE MG AND CA APPLE JUICE CA AND FE TUBE FEEDINGS STOP FEEDING FOR 2 HOURS BEFORE AND AFTER TB DRUGS 13

TAKE ON AN EMPTY STOMACH (1 HR BEFORE OR 2 HRS AFTER A MEAL) INH RIF,RBT EMB PZA QUINOLONES TAKE WITH FOOD ETHIONAMIDE / PAS TO REDUCE GI SIDE EFFECTS CLOFAZAMINE TO MAXIMZE ABSORPTION 14

WITHOUT REGARD TO MEALS PZA CYCLOSERINE RIFAPENTINE MOXIFLOXACIN Dusty in Basket 15

Resistance Primary mixed resistance Secondary resistance Risk factors Patient non-compliance Improper prescription Inadequate tissue penetration Heavy burden of disease RESISTANCE LOW DRUG LEVELS IN SERUM vs AT SITE OF INFECTION DRUG INTERACTION VOMITING 16

RESISTANCE POTENTIAL PROB. OF RESISTANCE NO ACTIVITY MAXIMUM EFFECT INCREASING POTENCY Population Curve 17

Question #4 Shortly after his MRI, JB s lab work shows rapidly deteriorating renal function. His CL cr is currently 20 ml/min. Which drug may need to have its dose modified? 1. INH 2. RIF 3. EMB 4. PZA DRUGS NEEDING ADJUSTMENT IN RENAL FAILURE EXCRETED RENALLY AS ACTIVE DRUG ACTIVE METABOLITE POTENTIALLY TOXIC METABOLITE HOW ADJUST DOSING? REDUCE DOSE EXTEND DOSING INTERVAL WHEN ADJUST? 50, 30, 10 ML/MIN AND SOMETIMES AT 80 18

ISONIAZID RENAL DOSING ACUTE RENAL FAILURE IN OVER DOSE CL CR <10, REDUCE DOSE BY 50% RIFAMPIN CAN CAUSE ACUTE RENAL FAILURE CL CR < 10, REDUCE DOSE BY 50% RENAL DOSING AMINOGLYCOSIDES SM, AMK, KAN, CAP CAUSE RENAL TOXICITY REDUCE DOSE AT 80 ML/MIN, 50, AND 10 OR EXTEND DOSING INTERVAL EMB EMB RENALLY EXCRETED AS ACTIVE DRUG REDUCE DOSE AT 50 ML/MIN, 10 ML/MIN 19

PZA RENAL DOSING DOSE CHANGES NOT GENERALLY REQUIRED BUT - CL CR < 50 REDUCE DOSE TO 12-20 MG/KG/D EXTEND INTERVAL AT 10 ML/MIN DIALYSIS AVOID USE RIFABUTIN CL < 30 ML/MIN REDUCE DOSE BY 50% QUINALONES RENAL DOSING OFLOXACIN, LEVOFLOXACIN REDUCE DOSES AT 50 ML/MIN EXTEND INTERVAL AT 10 ML/MIN MOXIFLOXACIN NO DOSAGE ADJUSTMENT NEEDED CYCLOSERINE REDUCE DOSE AT 80, 50, 10 ML 20

HEMODIALYSIS CAN GENERALLY GIVE STANDARD DAILY DOSES 3 TIMES A WEEK AFTER DIALYSIS MAY GET DIALYSIS UNIT TO DO DOT FOR YOU DO DRUG LEVELS RENAL FAILURE USE DRUGS METABOLIZED BY LIVER INH, RIF, PZA MOXIFLOXACIN VS LEVOFLOXACIN GIVE LOWER DOSES OF DRUGS RENALLY EXCRETED AS ACTIVE AGENTS GIVE SAME DOSE LESS FREQUENTLY DAILY DOSE 2 OR 3 TIMES A WEEK GIVE AFTER DIALYSIS MONITOR 21

CASE JB is successfully treated with steroids for his contrast t related renal failure. Three weeks later he develops elevated AST and ALT (>5x uln) and his total billi is at 4 and increasing. HEPATIC DYSFUNCTION ALLOW LIVER TO COOL OFF USE RENALLY EXCRETED DRUGS EMB, QUINALONE, AMG RESTART SUSPECT DRUGS ONE AT A TIME RIFABUTIN VS RIFAMPIN GIVE TWICE WEEKLY DOSES LEVOFLOXCIN VS MOXIFLOXACIN ADJUNCT AGENTS ACTIGALL INTERFERON ALFA MONITOR 22

Pixel PROBLEMS IN TX FAILURE TO RESPOND TB MENINGITIS RENAL FAILURE HEPATITIS NON-COMPLIANCE PSYCHIATRIC ISSUES/ SUBSTANCE ABUSE CAN T SWALLOW P ILLS GI INTOLERANCE ADVERSE DRUG REACTIONS ALLERGIES DRUG INTERACTIONS 23

DOT DIRECTLY OBSERVE PATIENT TAKING THE MEDICATION DOD DOT - OR - DOD? DIRECTLY OBSERVED DELIVERY 24

CAN T SWALLOW PILLS CRUSH OR USE ORAL LIQUIDS INH SYRUP RIF SIMPLE SYRUP JAM, HONEY, APPLESAUCE, ETC STABILITY? PZA, EMB SIMPLE SYRUP CRUSH IN JELLY, APPLE JUICE INJECTABLES CAN T SWALLOW INH RIF AMINOGLYCOSIDES and CAPREOMYCIN QUINILONES EMB SUPPOSITORIES 25

GI INTOLERANCE DIVIDE DOSES START WITH LOW DOSE AND INCREASE OVER SEVERAL DAYS GIVE AFTER MEALS MEDICATE H2 ANTAGONIST/ PPI METOCLOPRAMIDE PROMETHAZINE ZOFRAN LORAZEPAM PEJ TUBE ADR HIGH URIC ACID LEVELS ALLOPURINOL, COLCHICINE, PROBENECID MYALGIAS, ARTHRALGIAS NSAIDS EXERCISE 26

ADR GIVE AT BEDTIME SWITCH TO A DIFFERENT DRUG ALLERGY/ITCHING ANTIHISTAMINES STEROIDS DESENSITIZATION DESENSITIZATION ALLERGIES LOW DOSES GIVEN FREQUENTLY AND IN GRADUALLY INCREASING DOSES DO ONLY WHERE EMERGENCY TX IS AVAILABLE 27

DRUG INTERACTIONS PHENYTOIN WARFARIN HORMONE BASED CONTRACEPTIVES EFAVIRENZ HIV PROTEASE INHIBITORS QUESTION #5 Which team is going to win the SEC championship? hi Florida Gators Alabama Tide The what? 28

Jenifur waiting for the big game to start TB Hotline 1-800-4TB-INFO 29

THE END A.G. HOLLEY TB HOTLINE 1-800-4TB-INF0 30